List view / Grid view
The license agreement between Pfizer and the Medicines Patent Pool…
The license agreement between Pfizer and the Medicines Patent Pool (MPP) will enable access to Pfizer's antiviral candidate in 95 countries.
Paxlovid™, Pfizer's investigational oral antiviral candidate, displayed an 89 percent…
Paxlovid™, Pfizer's investigational oral antiviral candidate, displayed an 89 percent reduction in COVID-19 risks in Phase II/III study.
The UK's MHRA has given temporary emergency authorisation to Pfizer…
The UK's MHRA has given temporary emergency authorisation to Pfizer and BioNTech's COVID-19 vaccine, making it the first in the world to receive approval.
The companies and European Commission will soon enter contract negotiations…
The companies and European Commission will soon enter contract negotiations for the supply of their investigational COVID-19 vaccine candidate BNT162b2.
Pfizer is to manufacture and supply the investigational COVID-19 treatment…
Pfizer is to manufacture and supply the investigational COVID-19 treatment remdesivir for Gilead Sciences at one of its facilities.
Pfizer and BioNTech have initiated Phase I/II trials in the…
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted…
A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.
Lilly, Merck and Pfizer have announced how they will enable…
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
The pharmaceutical industry saw some notable mergers and acquisitions in…
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
Former FDA Commissioner, Scott Gottlieb, who stepped down from the…
Former FDA Commissioner, Scott Gottlieb, who stepped down from the administration in April, has joined Pfizer’s board of directors.
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4…
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...
